Key Points
- EVP Paul Mahon sold 8,300 United Therapeutics shares at an average price of $482.03, generating approximately $4.00 million. The transaction reduced his holdings by 15.52%, leaving him with 45,172 shares.
- United Therapeutics exceeded quarterly EPS expectations, reporting $7.27 versus the $6.86 consensus estimate, although revenue of $783.3 million fell short of forecasts and declined 1.9% year over year.
- Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of about $646. Investors are also watching the FDA review of Tyvaso’s potential label expansion for idiopathic pulmonary fibrosis, while competition continues to pressure existing Tyvaso sales.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total value of $4,000,849.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $21,774,259.16. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Price Performance
UTHR stock opened at $490.24 on Friday. United Therapeutics Corporation has a 1 year low of $375.61 and a 1 year high of $609.35. The firm has a market capitalization of $21.03 billion, a PE ratio of 17.54, a price-to-earnings-growth ratio of 2.46 and a beta of 0.56. The business has a 50 day simple moving average of $527.06 and a 200-day simple moving average of $539.91.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm's revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $6.41 earnings per share. On average, equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.
More United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application seeking to expand the label for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF). The filing is supported by Phase 3 TETON-1 and TETON-2 data, which showed statistically significant lung-function improvement and reduced clinical worsening. FDA review is expected to conclude in late April 2027. A successful expansion could substantially increase Tyvaso’s addressable market. FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
- Neutral Sentiment: Analyst sentiment remains broadly favorable, with United Therapeutics carrying a consensus “Moderate Buy” rating and an average price target of about $646, although some firms have reduced their targets and Morgan Stanley’s target is near the current trading range. This signals long-term optimism but also highlights valuation and execution concerns.
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, reducing her direct ownership by 2.84%. EVP Paul Mahon separately sold 8,300 shares for about $4.00 million, cutting his position by 15.52%. The transactions may reinforce near-term investor caution, although Rothblatt’s sale was disclosed as occurring under a pre-arranged trading plan. United Therapeutics Insider Sale Filing
- Negative Sentiment: United Therapeutics’ second-quarter results showed Tyvaso revenue declining 4% year over year, with management citing competition across nebulized Tyvaso, Tyvaso DPI and Remodulin. The IPF opportunity is strategically important because investors are looking for growth to offset weakness in the existing pulmonary hypertension business.
Analysts Set New Price Targets
Several brokerages have recently weighed in on UTHR. Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Finally, Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $646.00.
Check Out Our Latest Analysis on UTHR
Hedge Funds Weigh In On United Therapeutics
Several large investors have recently modified their holdings of the business. Toth Financial Advisory Corp increased its position in shares of United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the 2nd quarter valued at about $30,000. Entrust Financial LLC acquired a new position in United Therapeutics in the fourth quarter valued at about $31,000. Caitlin John LLC acquired a new position in United Therapeutics in the second quarter valued at about $37,000. Finally, International Assets Investment Management LLC boosted its stake in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after buying an additional 64 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
